Neal Fischbach, MD
Assistant Professor of Medicine (Medical Oncology)Cards
About
Titles
Assistant Professor of Medicine (Medical Oncology)
Assistant Medical Director, Clinical Trials Office
Biography
Dr. Neal Fischbach is a medical oncologist focusing on breast cancer. He attended the University of Pennsylvania and Harvard University Medical School and completed his fellowship at the University of California San Francisco. He is the Assistant Medical Director to the Clinical Trials Office for the Care Centers, coordinating clinical trials activities across Yale’s network of Care Centers.
Appointments
Medical Oncology and Hematology
Assistant ProfessorPrimary
Other Departments & Organizations
- Cancer Prevention and Control
- Internal Medicine
- Medical Oncology & Hematology
- Medical Oncology and Hematology
- Subset Medical Oncology Faculty
- Yale Cancer Center
- Yale Medicine
Education & Training
- Fellowship
- University of California - San Francisco (2002)
- Residency
- University of California - San Francisco (1999)
- MD
- Harvard Medical School (1995)
Research
Publications
2024
Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer
Cecchini M, Salem R, Robert M, Czerniak S, Blaha O, Zelterman D, Rajaei M, Townsend J, Cai G, Chowdhury S, Yugawa D, Tseng R, Arbelaez C, Jiao J, Shroyer K, Thumar J, Kortmansky J, Zaheer W, Fischbach N, Persico J, Stein S, Khan S, Cha C, Billingsley K, Kunstman J, Johung K, Wiess C, Muzumdar M, Spickard E, Aushev V, Laliotis G, Jurdi A, Liu M, Escobar-Hoyos L, Lacy J. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer. JAMA Oncology 2024, 10: 1027-1035. PMID: 38900452, PMCID: PMC11190830, DOI: 10.1001/jamaoncol.2024.1575.Peer-Reviewed Original ResearchProgression-free survivalPancreatic ductal adenocarcinomaOverall survivalCtDNA levelsPhase 2 nonrandomized controlled trialAnalysis of circulating tumor DNAMedian progression-free survivalResectable pancreatic ductal adenocarcinomaControlled trialsAssess surgical candidacyBaseline ctDNA levelModified 5-fluorouracilResectable pancreatic cancerPancreatic protocol computed tomographyAssociated with recurrenceTumor molecular featuresAggressive malignant tumorKaplan-Meier estimatesRandomized clinical trialsStandard of careCtDNA-positivePreoperative cyclesNonrandomized controlled trialsUnresectable diseaseModified FOLFIRINOXImpact of semaglutide and tirzepatide administration on weight in women with stage I-III breast cancer.
Fischbach N, Zhou B, Deng Y, Parsons K, Shelton A, Lustberg M. Impact of semaglutide and tirzepatide administration on weight in women with stage I-III breast cancer. Journal Of Clinical Oncology 2024, 42: e24140-e24140. DOI: 10.1200/jco.2024.42.16_suppl.e24140.Peer-Reviewed Original ResearchStage I-III breast cancerI-III breast cancerAdverse breast cancer outcomesBreast cancerMaximal weight lossMean weight lossBreast cancer survivorsDistant breast cancer recurrenceGLP-1 agonistsBreast cancer outcomesStage distributionClinically meaningful weight lossBreast cancer recurrenceWeight loss maintenanceUntreated patientsCancer survivorsMeasures regression analysisIncidence of diabetesWeight lossTreated patientsRetrospective analysisHealth NetworkMental healthCancer outcomesGLP-1Using an AI trial screening tool to assess language as a barrier for enrollment of underrepresented minorities in cancer clinical trials.
Corvese L, Weiss C, Huie S, Zhou B, Deng Y, Gong G, Kunz P, Fischbach N. Using an AI trial screening tool to assess language as a barrier for enrollment of underrepresented minorities in cancer clinical trials. Journal Of Clinical Oncology 2024, 42: e13586-e13586. DOI: 10.1200/jco.2024.42.16_suppl.e13586.Peer-Reviewed Original ResearchClinical trialsCancer clinical trialsTrial enrollmentPercentage of patientsYale Cancer CenterClinical trial enrollmentLimitations of clinical trialsTreating providersEnrolling patientsCancer CenterUnique patientsBreast programPatientsPatient-matchedEnrollment ratesStudy-related activitiesScreening toolTrial participantsTrialsCancerOffice staffClinicEnrollmentLanguage barriersNon-English
2023
Prognostic impact of reduced HER2 protein expression in post-neoadjuvant therapy resection specimens: A single institution experience and review of the literature
Mogica J, Tang H, Liang Y, Zhong M, Hui P, Harigopal M, Krishnamurti U, Fischbach N, Zhan H. Prognostic impact of reduced HER2 protein expression in post-neoadjuvant therapy resection specimens: A single institution experience and review of the literature. The Breast 2023, 72: 103586. PMID: 37812963, PMCID: PMC10568274, DOI: 10.1016/j.breast.2023.103586.Peer-Reviewed Original ResearchConceptsHER2 IHC 3Human epidermal growth factor receptor 2Kaplan-Meier survival analysisHER2-IHC expressionPathologic complete responseResidual diseaseIHC 3Breast cancerIHC expressionSurvival analysisSuperior disease-free survivalEpidermal growth factor receptor 2Intensive adjuvant therapyPost-therapy surveillanceYale Cancer CenterDisease-free survivalGrowth factor receptor 2Recurrence-free survivalSingle institution experienceLow recurrence rateFactor receptor 2HER2 protein expressionAdjuvant trialsNeoadjuvant treatmentAdjuvant therapyMetastatic breast cancer (MBC) with ultra-high tumor mutational burden (UHTMB): A comprehensive genomic profiling (CGP) study.
Fanucci K, Lustberg M, Fischbach N, Pelletier M, Sivapiragasam A, Ashok Kumar P, Kallem M, Danziger N, Sokol E, Sivakumar S, Pavlick D, Ross J, Pusztai L. Metastatic breast cancer (MBC) with ultra-high tumor mutational burden (UHTMB): A comprehensive genomic profiling (CGP) study. Journal Of Clinical Oncology 2023, 41: 1036-1036. DOI: 10.1200/jco.2023.41.16_suppl.1036.Peer-Reviewed Original ResearchMetastatic breast cancerLobular histologyBreast cancerHER2 IHCGenomic alterationsComprehensive genomic profiling studyPD-L1 gene amplificationImmune checkpoint inhibitor treatmentMicrosatellite instabilityAxillary LN metastasisMetastatic site biopsySubset of ptsStage IV diseaseCheckpoint inhibitor treatmentPD-L1 expressionTumor mutational burdenMutations/MbMSI-high statusHER2 IHC resultsGenomic profiling studiesSite biopsiesSP142 assayLN metastasisMetastatic diseaseHigh TMBDecreased HER2 expression in residual disease following neoadjuvant therapy in patients with HER2-positive breast cancer.
Paredes Mogica J, Tang H, Fischbach N, Zhan H. Decreased HER2 expression in residual disease following neoadjuvant therapy in patients with HER2-positive breast cancer. Journal Of Clinical Oncology 2023, 41: e12621-e12621. DOI: 10.1200/jco.2023.41.16_suppl.e12621.Peer-Reviewed Original ResearchNeo-adjuvant therapyKaplan-Meier survival analysisHER2 IHC 3Pathologic complete responseResidual diseaseBreast cancerHER2 expressionAdjuvant therapyNeoadjuvant therapyEpidermal growth factor receptor 2 overexpressionHuman epidermal growth factor receptor 2 (HER2) overexpressionSurvival analysisHER2-positive breast cancerAggressive adjuvant therapyHER2-IHC expressionPost-therapy surveillanceResidual invasive tumorTrastuzumab/pertuzumabYale Cancer CenterRecurrence-free survivalBreast cancer outcomesAdo-trastuzumab emtansineLow recurrence rateStandard of careAssociation of pre
2022
Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC.
Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm DL, Pusztai L. Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC. Clinical Cancer Research 2022, 28: 3720-3728. PMID: 35903931, PMCID: PMC9444984, DOI: 10.1158/1078-0432.ccr-22-0862.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsTriple-negative breast cancerNon-AA patientsEvent-free survivalPhase I/II clinical trialsClinical trialsNeoadjuvant chemotherapyOverall survivalAA patientsEarly-stage triple-negative breast cancerIncidence of irAEsPathologic complete response rateSignificant associationMultivariate logistic regression analysisTumor-infiltrating lymphocyte countsComplete response ratePrimary efficacy endpointPD-L1 statusProportional hazards modelLogistic regression analysisAfrican American womenEFS ratesNeoadjuvant immunotherapyEfficacy endpointAdverse eventsThe mutational profile of ER-, PR+, HER2- metastatic breast cancer.
Fischbach N, Huang R, Lustberg M, Pelletier M, Pusztai L, Sivakumar S, Sokol E, Ross J, Levy M. The mutational profile of ER-, PR+, HER2- metastatic breast cancer. Journal Of Clinical Oncology 2022, 40: 1025-1025. DOI: 10.1200/jco.2022.40.16_suppl.1025.Peer-Reviewed Original ResearchTriple-negative breast cancerComprehensive genomic profilingMetastatic breast cancerBreast cancerClinical trialsPathology reportsMutational profileHER2- metastatic breast cancerConsecutive breast cancersAnti-estrogen therapyNegative breast cancerPD-L1 IHCPotential therapeutic implicationsHigh rateEndocrine therapyEstrogen therapyPatient ageFoundation MedicineKRAS alterationsRare subtypeHER2 expressionClinical behaviorReceptor phenotypeBreast carcinomaTreatment strategiesClinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC.
Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm D, Pusztai L. Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC. Journal Of Clinical Oncology 2022, 40: 516-516. DOI: 10.1200/jco.2022.40.16_suppl.516.Peer-Reviewed Original ResearchImmune-related adverse eventsTriple-negative breast cancerMultivariate logistic regression analysisPD-L1 statusLogistic regression analysisAA raceOverall survivalPathologic responseClinical trialsBreast cancerEarly-stage triple-negative breast cancerIncidence of irAEsPhase I/II trialPathologic complete response rateSignificant associationPhase I/II clinical trialsBaseline body mass indexSafety of immunotherapyWeekly nab-paclitaxelCharlson Comorbidity IndexComplete response ratePrimary efficacy endpointPD-L1 expressionBody mass indexBreast cancer recurrenceAuthor Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
Foldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L. Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer. Npj Breast Cancer 2022, 8: 17. PMID: 35115541, PMCID: PMC8814070, DOI: 10.1038/s41523-022-00392-3.Peer-Reviewed Original Research
Clinical Trials
Current Trials
Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma
HIC ID2000029793RoleSub InvestigatorPrimary Completion Date04/30/2028Recruiting ParticipantsParallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
HIC ID2000032279RoleSub InvestigatorPrimary Completion Date12/31/2033Recruiting ParticipantsRandomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
HIC ID2000032879RoleSub InvestigatorPrimary Completion Date12/31/2026Recruiting ParticipantsRandomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
HIC ID2000032098RoleSub InvestigatorPrimary Completion Date03/31/2025Recruiting ParticipantsA Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
HIC ID2000031542RoleSub InvestigatorPrimary Completion Date01/31/2026Recruiting Participants
Academic Achievements & Community Involvement
Clinical Care
Overview
Neal Fischbach, MD, is a medical oncologist who focuses on caring for people with breast cancer.
“My priority is getting people the very best cancer care available in whatever environment they prefer,” Dr. Fischbach says. “I am focused not only on treating cancer but the impact a cancer diagnosis has on family members and friends. I am committed to making the latest advances in cancer care available to people through participation in clinical trials.”
As an assistant professor of medicine (medical oncology) at Yale School of Medicine, Dr. Fischbach also serves as the assistant medical director of the clinical trials office for the Smilow Cancer Hospital Care Center Network, coordinating clinical trial activities across Yale’s care centers.
He completed his medical training at Harvard Medical School and pursued a residency in internal medicine, followed by a fellowship in hematology and oncology at the University of California, San Francisco.
Clinical Specialties
Medical Oncology
Fact Sheets
Inflammatory Breast Cancer
Learn More on Yale MedicineHormonal Therapy for Cancer
Learn More on Yale MedicineBreast Cancer
Learn More on Yale MedicinePediatric Chemotherapy
Learn More on Yale Medicine
Yale Medicine News
News
News
- October 09, 2024
Smilow Cares - Cannabis in Cancer Care: A Historical Overview and Current Perspectives
- June 20, 2024
Chemotherapy Before Surgery Benefits Some Patients With Pancreatic Cancer
- June 17, 2024
Dr. Neal Fischbach on Yale Cancer Answers
- June 12, 2024Source: Yale New Haven Health
Yale New Haven Health and Yale University celebrate Innovation Awards
Get In Touch
Contacts
Appointment Number
Clinic Fax Number
Mailing Address
Yale Cancer Center
5520 Park Avenue, Suite 307
Trumbull, CT 06611
United States
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.